A siRNA for inhibiting the expression of the programmed cell death-ligand 1 gene, its conjugates, pharmaceutical compositions, and their uses.

Liver-targeted siRNA conjugates with modified nucleotides provide effective PD-L1 inhibition, addressing safety and efficacy issues of existing drugs, offering improved treatment options for diseases like hepatitis B and cancer.

CN117881783BActive Publication Date: 2024-12-03SUZHOU SIRAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380011914.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2023-11-23
Publication Date
2024-12-03
Estimated Expiration
2043-11-23

AI Technical Summary

Technical Problem

Current drugs targeting PD-L1, such as antibodies and small molecules, have high adverse reaction rates and poor safety, while existing siRNA drugs lack clinical presence, necessitating the development of liver-specific siRNA conjugates for effective PD-L1 gene inhibition.

Method used

Development of siRNA sequences with modified nucleotides and conjugates, specifically designed for liver targeting, to inhibit PD-L1 gene expression, using a sense and antisense chain with nucleotide sequences and chemical modifications, and a conjugated group to enhance delivery and efficacy.

Benefits of technology

The siRNA conjugates demonstrate high PD-L1 mRNA inhibitory activity, improved safety, and long-term efficacy, reducing systemic side effects and allowing longer dosing intervals, enhancing treatment of diseases related to PD-L1 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117881783B_ABST
    Figure CN117881783B_ABST
Patent Text Reader

Abstract

The present invention relates to a siRNA for inhibiting the expression of programmed cell death-ligand 1 gene, a conjugate thereof, a pharmaceutical composition and a use thereof, wherein the siRNA comprises a sense strand and an antisense strand, each nucleotide in the siRNA is independently a modified or unmodified nucleotide, the sense strand comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NO.1 to 12 or a nucleotide sequence with no more than 3 base mutations in the above sequence, and the antisense strand comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NO.13 to 24 or a nucleotide sequence with no more than 5 base mutations in the above sequence. The siRNA drug of the present invention has liver targeting specificity, has better safety than small molecule drugs and antibody drugs, and has long-term efficacy, can achieve longer dosing intervals in clinical practice, and has better patient compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a siRNA for inhibiting the expression of programmed cell death-ligand 1 gene, a conjugate and a pharmaceutical composition thereof and uses thereof. Background Art

[0002] Programmed cell death 1ligand 1 (PD-L1), also known as surface antigen cluster of differentiation 274 (cluster of differentiation 274, CD274) or B7 homolog 1 (B7-H1), is a type I transmembrane protein with a size of 40 kDa, encoded by the CD274 gene. PD-L1 is expressed on different tissue cells such as T cells, epithelial cells, and endothelial cells, and its expression is upregulated in many tumors.

[0003] PD-L1 is the main ligand of PD-1. The interaction between ligand PD-L1 and receptor PD1 can induce phosphorylation of intracellular immunoreceptor tyrosine-based switch motifs (ITSMs) and receptor tyrosine-based inhibitory motifs (ITIMs), thereby inhibiting T cell activation and cytokine production. During normal tissue infection or inflammation, this interaction is important for preventing autoimmunity by maintaining immune response homeostasis. In the tumor microenvironment, this interaction can inactivate effector T cells, thereby providing immune escape for tumor cells.

[0004] In addition, there are articles reporting (Sun Y et al., Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1; 318(1): G162-G173.) that viruses regulate the PD-1 / PD-L1 pathway to improve infectivity. During hepatitis B virus (HBV) infection, HBV can increase the expression of PD-L1 through the PTEN / β-catenin / c-Myc signaling pathway, thereby inhibiting T cell responses and ultimately promoting HBV immune escape. Targeting this signaling pathway is a potential strategy for treating chronic hepatitis B.

[0005] Currently, most of the drugs targeting PD-L1 that are on the market or in clinical trials are antibodies or small molecules, such as Envolizumab, Sugemalimab, Durvalumab, APL-502, CA-170, etc. Most of the indications of these drugs under development are in the field of tumors. They are systemic drugs with high adverse reaction rates and poor safety in clinical practice. They are rarely used in the treatment of hepatitis B. Among the currently marketed drugs, only Envolizumab (ASC22) is undergoing clinical trials in the United States for the indication of hepatitis B. Preclinical studies have shown that in the woodchuck model infected with hepatitis B virus, the combination of ASC22 and entecavir can reduce the surface antigen level (Balsitis S et al., PLoS One. 2018 Feb 14; 13(2): e0190058.), and Phase IIa clinical data showed that a single dose of 0.3, 1.0 or 2.5 mg / kg ASC22 resulted in a dose-dependent reduction in HBsAg.

[0006] Currently in the field of nucleic acids, there is only one oligonucleotide (ASO) drug targeting PD-L1, RO-9191863, from Roche in the clinical stage of the treatment of hepatitis B. Generally, ASO is slightly inferior to siRNA drugs in terms of effectiveness and long-term effectiveness, and has the characteristics of systemic distribution. The liver-specific delivery is not as good as the siRNA drug form conjugated with liver-targeted molecules. siRNA drugs can be conjugated with liver-targeted molecules to specifically deliver siRNA drugs targeting PD-L1 to the liver, which can specifically downregulate the level of PD-L1 molecules in the liver and reduce the systemic side effects of small molecules, antibodies, and ASO drugs.

[0007] So far, although there are some patents for siRNA targeting PD-L1, no siRNA drugs targeting PD-L1 have been launched on the market, and no siRNA drugs are even in the clinical research stage. Therefore, there is still a need to continue to develop siRNA drugs that can inhibit the expression of the PD-L1 gene. Summary of the invention

[0008] The object of the present invention is to provide the following siRNA and its modified sequence that can specifically inhibit the expression of PD-L1 gene in cells. The pharmaceutical composition and siRNA conjugate containing the siRNA of the present invention can effectively deliver the siRNA of the present invention to target tissues and / or cells, thereby showing high drug potential in the treatment or prevention of diseases related to PD-L1 expression.

[0009] In order to achieve the above object, the technical solution adopted by the present invention is:

[0010] In a first aspect, the present invention provides an siRNA for inhibiting the expression of programmed cell death-ligand 1 gene, which comprises a sense chain and an antisense chain, wherein the sense chain comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NO.1 to 12 or a nucleotide sequence with no more than 3 base mutations in the above sequence, and the antisense chain comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NO.13 to 24 or a nucleotide sequence with no more than 5 base mutations in the above sequence.

[0011] According to certain embodiments, the positive strand includes a nucleotide sequence with no more than 2 base mutations and no more than 1 base mutation compared to any one of the nucleotide sequences shown in SEQ ID NOs. 1 to 12.

[0012] According to certain embodiments, the base mutation of the sense chain can be at any position of the nucleotide sequence, for example, at any one, two or three of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth and nineteenth positions.

[0013] According to certain embodiments, the antisense strand includes a nucleotide sequence with no more than 5 base mutations, a nucleotide sequence with no more than 4 base mutations, a nucleotide sequence with no more than 3 base mutations, a nucleotide sequence with no more than 2 base mutations, and a nucleotide sequence with no more than 1 base mutation compared to any one of the nucleotide sequences shown in SEQ ID NOs. 13 to 24.

[0014] According to certain embodiments, the base mutation of the antisense strand can be at any position of the nucleotide sequence, for example, any one, two, three, four or five of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, and twenty-first positions.

[0015] According to certain embodiments, in the 5' to 3' direction, the base mutation of the sense strand is at the 3' end of its nucleotide sequence, and the base mutation of the antisense strand is at any one or more of the 5' end, the 2nd to 8th positions, and the last two positions of the 3' end of its nucleotide sequence.

[0016] According to certain embodiments, the base mutation includes base substitution, insertion or deletion.

[0017] In certain embodiments, the modified nucleotides are 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides, 2'-O-CH2-CH2-O-CH3-modified nucleotides, 2'-O-CH2-CH=CH2-modified nucleotides, 2'-CH2-CH2-CH=CH2-modified nucleotides, 2'-deoxy nucleotides, 2'-methoxyethyl-modified nucleotides, phosphorothioate-modified nucleotides, VP-modified nucleotides, LNA, ENA, cET BNA, UNA, GNA and SAFE-01, wherein R1 in the structural formula shown in SAFE-01 is H, OH or CH3, and Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom.

[0018] Further, R1 is CH3.

[0019] In certain embodiments, the number of modified nucleotides in the sense strand is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, or nineteen.

[0020] In certain embodiments, the number of modified nucleotides in the antisense strand is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or twenty-one.

[0021] In certain embodiments, all of the nucleotides in the sense strand and the antisense strand are modified nucleotides.

[0022] In certain embodiments, in the 5' to 3' direction, nucleotides 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and nucleotides 2, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides.

[0023] In certain further embodiments, the nucleotides at other positions of the sense strand are 2'-methoxy modified nucleotides.

[0024] In certain further embodiments, in the 5' to 3' direction, the 6th position of the antisense strand is a 2'-fluoro-modified nucleotide or SAFE-01, and the 7th position of the antisense strand is a 2'-methoxy-modified nucleotide or SAFE-01.

[0025] Preferably, SAFE-01 is Ago, Ggo, Cgo or Ugo.

[0026] In certain further embodiments, the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides, wherein the other positions refer to positions other than the 2nd, 6th, 7th, 14th and 16th positions.

[0027] In certain further embodiments, at least one of the following linkages between nucleotides in the siRNA is a phosphorothioate linkage:

[0028] The connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand;

[0029] The connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand;

[0030] The connection between the first nucleotide and the second nucleotide at the 3' end of the sense strand;

[0031] The connection between the second nucleotide and the third nucleotide at the 3' end of the sense strand;

[0032] The connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand;

[0033] The connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand;

[0034] The connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand;

[0035] The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.

[0036] In certain further embodiments, the 3' end of the sense strand is a phosphorothioate group, and the 5' end of the antisense strand is a VP-modified nucleotide.

[0037] In certain embodiments, the siRNA is selected from any sequence in Table 2 or Table 3, wherein a sense strand and an antisense strand of a double-strand number constitute one siRNA.

[0038] The second aspect of the present invention provides a siRNA conjugate, which includes one or more of the above-mentioned siRNAs, and a conjugated group conjugated to the siRNA.

[0039] In certain embodiments, the conjugated group is derived from compound SA51, the structural formula of which is:

[0040]

[0041] Furthermore, the number of compound SA51 in the conjugated group is 2 to 4, and the 2 to 4 compounds SA51 are sequentially connected by chemical bonds.

[0042] In certain embodiments, the conjugate group is attached to the 3' end and / or the 5' end of the sense strand.

[0043] In certain embodiments, the siRNA conjugate has the following structural formula:

[0044]

[0045] in, represents the duplex formed by the siRNA of the present disclosure, and X is O or S.

[0046] The third aspect of the present invention provides a pharmaceutical composition, which includes the above-mentioned siRNA or the above-mentioned siRNA conjugate, and a pharmaceutically acceptable carrier or excipient.

[0047] In certain embodiments, the pharmaceutical composition is used to inhibit programmed cell death-ligand 1 gene expression.

[0048] The fourth aspect of the present invention provides use of the above siRNA, or the above siRNA conjugate, or the above pharmaceutical composition for preparing a medicament for treating and / or preventing diseases related to PD-L1 gene expression.

[0049] In certain embodiments, the disease is viral hepatitis or cancer.

[0050] Furthermore, the viral hepatitis is caused by infection with hepatitis B virus, hepatitis C virus, or hepatitis D virus.

[0051] In certain embodiments, the above siRNA, or the above siRNA conjugate, or the above pharmaceutical composition is formulated and administered to a subject according to a desired dose.

[0052] In certain embodiments, the above siRNA, or the above siRNA conjugate, or the above pharmaceutical composition is administered by subcutaneous injection, intravenous injection, intrathecal injection, or intramuscular injection.

[0053] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art:

[0054] The siRNA disclosed in the present invention is a humanized PD-L1 siRNA sequence, and its conjugate and pharmaceutical composition have good stability and high PD-L1 mRNA inhibitory activity. The siRNA drug has liver targeting specificity, better safety than small molecule drugs and antibody drugs, and long-term efficacy, which can achieve longer dosing intervals in clinical practice and better patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 This is a graph showing the IC50 test results of the siRNA of Example 5 in SNU-387 cells;

[0056] Figure 2 The figure shows the activity results of the siRNA of Example 7 in HDI mice on the 7th and 28th days. DETAILED DESCRIPTION

[0057] It should be noted that, unless otherwise defined, the technical terms or scientific terms used in this application should have the common meanings understood by technicians in the relevant field.

[0058] The experimental methods in the following examples are conventional methods unless otherwise specified. The raw materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.

[0059] definition

[0060] In the above and below, 2'-methoxy-modified nucleotide refers to a nucleotide in which the hydroxyl group at the 2'-ribose group of the nucleotide is replaced by a methoxy group; similarly, 2'-fluoro-modified nucleotides, 2'-O-CH2-CH2-O-CH3-modified nucleotides, 2'-O-CH2-CH=CH2-modified nucleotides, 2'-CH2-CH2-CH=CH2-modified nucleotides, 2'-deoxy nucleotides, and 2'-methoxyethyl-modified nucleotides respectively refer to nucleotides in which the hydroxyl group at the 2'-ribose group of the nucleotide is replaced by the corresponding group.

[0061] Phosphorothioate-modified nucleotides refer to nucleotides in which one of the oxygen atoms in the phosphodiester bond in the phosphate group of the nucleotide is replaced by a sulfur atom.

[0062] VP-modified nucleotides refer to nucleotides in which the phosphate group of the nucleotide is replaced by a vinyl phosphate group. In some embodiments, the 5'-terminal phosphate group of the antisense strand is replaced by VP.

[0063] LNA is shown in formula (1), ENA is shown in formula (2), cET BNA is shown in formula (3), UNA is shown in formula (4), GNA is shown in formula (5), and VP is shown in formula (6):

[0064]

[0065] In the above formulae (1) to (6), Base represents a natural nucleobase, a modified nucleobase, or a universal base, such as A, U, G, or C. In the above formulae (4) to (6), R is selected from H, OH, or alkoxy (O-alkyl).

[0066] The structural formula of SAFE-01 is Wherein, R1 is H, OH or CH3, and Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom. According to some embodiments, R1 is H. According to some embodiments, R1 is OH. According to some embodiments, R1 is CH3.

[0067] In the above and below, especially when describing the preparation method of the siRNA, pharmaceutical composition or siRNA conjugate of the present disclosure, unless otherwise specified, the nucleoside monomer refers to the modified or unmodified nucleoside phosphoramidite monomer used in the solid phase phosphoramidite synthesis according to the type and order of nucleotides in the siRNA or siRNA conjugate to be prepared. Solid phase phosphoramidite synthesis is a method used in RNA synthesis known to those skilled in the art. The nucleoside monomers used in the present disclosure are all commercially available.

[0068] In the context of the present disclosure, unless otherwise specified, "conjugation" refers to the connection between two or more chemical moieties, each having a specific function, in a covalently linked manner; accordingly, "conjugate" refers to a compound formed by covalently linking the chemical moieties. Further, "siRNA conjugate" means a compound formed by covalently linking one or more chemical moieties having a specific function to siRNA. siRNA conjugates should be understood as a general term for multiple siRNA conjugates or an siRNA conjugate shown by a certain chemical formula, depending on the context. In the context of the present disclosure, "conjugated molecule" should be understood as a specific compound that can be conjugated to siRNA through a reaction to ultimately form the siRNA conjugate of the present disclosure.

[0069] Various hydroxyl protecting groups can be used in the present disclosure. In general, the protecting group makes the chemical functional group insensitive to specific reaction conditions, and can be added and removed on the functional group in the molecule without substantially damaging the rest of the molecule. Representative hydroxyl protecting groups are disclosed in Beaucage et al., Tetrahedron 1992, 48, 2223-2311, and Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2ded, John Wiley & Sons, New York, 1991, and the above-mentioned documents are each incorporated herein by reference in their entirety. In some embodiments, the protecting group is stable under alkaline conditions, but can be removed under acidic conditions. In some embodiments, the non-exclusive examples of hydroxyl protecting groups that can be used herein include dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (Mox). In some embodiments, non-exclusive examples of hydroxy protecting groups that may be used herein include Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-dimethoxytrityl), and TMTr (4,4',4"-trimethoxytrityl).

[0070] The pharmaceutically acceptable carrier described in the present disclosure can be a carrier conventionally used in the field of siRNA administration, such as, but not limited to, magnetic nanoparticles (such as nanoparticles based on Fe3O4 or Fe2O3), carbon nanotubes, mesoporous silicon, calcium phosphate nanoparticles, polyethyleneimine (PEI), polyamidoamine (PAMAM) dendrimer, poly(L-lysine), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly (D&L-lactic / glycolic acid) copolymer (PLGA), poly (2-aminoethyl ethylene phosphate) and poly (2-aminoethyl ethylene phosphate). The pharmaceutically acceptable other excipients may include one or more of a pH buffer, a protective agent, and an osmotic pressure regulator.

[0071] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0072] The term "subject", as used herein, refers to any animal, such as a mammal or marsupial. Subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cows, rabbits, sheep, rats, and poultry of any kind.

[0073] As used herein, "treatment" refers to an approach to obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. In addition, a therapeutic benefit is obtained by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, although the subject may still be afflicted with the underlying disorder.

[0074] As used herein, "prevention" refers to an approach to obtaining beneficial or desired results, including but not limited to a prophylactic benefit. To obtain a "prophylactic benefit," siRNA, siRNA conjugate, or pharmaceutical composition can be administered to a subject at risk for a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have been made.

[0075] The technical solution provided by the present invention is further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and will not limit the protection scope of the present invention.

[0076] Example 1 Synthesis of siRNA

[0077] Herein, if the actual source of a reagent is not given, such reagent can be obtained from any supplier of molecular biology reagents and has the quality / purity standards that meet the molecular biology application standards.

[0078] The PD-L1 siRNA sequence was synthesized at 200 nanomoles (nmol) on a Dr.Oligo48 synthesizer (Biolytic) using solid support-mediated phosphoramidite chemistry. The solid support was a universal solid support (Shenzhen Comma Biotech). Nucleoside monomer raw materials 2'-F RNA, 2'-O-methyl RNA and other nucleoside phosphoramidite monomers were purchased from Shanghai Zhaowei or Suzhou Jima. The coupling time of all phosphoramidites (50mM acetonitrile solution) was 6 minutes (min), 5-ethylthio-1H-tetrazole (ETT) was used as an activator (0.6M acetonitrile solution), 0.22M PADS dissolved in 1:1 volume ratio of acetonitrile and trimethylpyridine (Suzhou Kelema) solution was used as a sulfurization reagent, the sulfurization reaction time was 3 minutes (min), and iodine pyridine / water solution (Kelema) was used as an oxidant, and the oxidation reaction time was 2 minutes (min).

[0079] After solid phase synthesis, the oligoribonucleotides were cleaved from the solid support and soaked in a 3:1 28% ammonia and ethanol solution at 50°C for 16 hours. Then, the supernatant was transferred to another centrifuge tube, concentrated and evaporated to dryness, and purified by C18 reverse chromatography with a mobile phase of 0.1MTEAA and acetonitrile, and DMTr was removed using a 3% trifluoroacetic acid solution. The target oligonucleotides were collected and freeze-dried, identified as the target product by LC-MS, and then quantified by UV (260nm).

[0080] The obtained single-stranded oligonucleotides are annealed according to the two complementary sequences in an equal molar ratio, and the resulting double-stranded siRNA is dissolved in 1X PBS and adjusted to the required concentration for the experiment. These monomers are linked to each other into oligonucleotides through 5'-3'-phosphodiester bonds.

[0081] Example 2 Preparation of siRNA conjugates

[0082] 1. Galnac target preparation

[0083] In this example, the synthesis route of compound SA51 (I-1-7) is as follows:

[0084]

[0085] 1. Preparation of intermediate 2-1

[0086]

[0087] Compound (R)-(+)-N-benzyl-3-hydroxypyrrolidine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (16.9mmol, 3.0g) and imidazole (3.0equiv, 50.7mmol, 3.45g) were placed in a clean dry reaction bottle, 50mL of acetonitrile was added, and tert-butyldimethylsilyl chloride (1.3equiv, 21.9mmol, 3.31g) was slowly added at room temperature, and then stirred at room temperature for 12 hours. After the reaction, 100mL of ethyl acetate was added to the reaction solution, and washed with 100mL of saturated sodium bicarbonate solution and 100mL of saturated brine, the organic phase was dried, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1-5 / 1) to obtain a colorless oil compound 2-1 (4.9g, 16.8mmol, 99% yield). Compound 2-1 molecular formula: C 17 H 29 ONSi, molecular weight: 291.2, LC-MS measured: 292.4 (M+H).

[0088] 2.2 Preparation of intermediate 2-2

[0089]

[0090] Compound 2-1 (16.8 mmol, 4.9 g) was placed in a clean dry reaction bottle, 100 mL of methanol was added, palladium carbon (wet basis, 10% Pd / C) (10% wt, 490.0 mg) was added under hydrogen at room temperature, and then stirred at room temperature for 12 hours. After the reaction, the palladium carbon was filtered off, and the filtrate was concentrated to obtain a crude product of white solid compound 2-2 (3.31 g, 16.5 mmol, 98% yield), which was directly used in the next step without purification. Compound 2-2 molecular formula: C 10 H 23 ONSi, molecular weight: 201.1, LC-MS measured: 202.3 (M+H).

[0091] 2.3 Preparation of intermediate 2-3

[0092]

[0093] The compound N-benzyloxycarbonyl-L-serine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (15.0 mmol, 3.58 g) was placed in a clean dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 22.5 mmol, 8.53 g), compound 2-2 (1.1 equiv, 16.5 mmol, 3.31 g) and N,N-diisopropylethylamine (3.0 equiv, 45.0 mmol, 5.78 g) were added at room temperature, followed by stirring at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered and concentrated. The obtained crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 3) to obtain a white solid compound 2-3 (4.5 g, 10.65 mmol, 63% two-step yield). Compound 2-3 molecular formula: C 21 H 34 O5N2Si, molecular weight: 422.2, LC-MS measured: 423.3 (M+H). 1H NMR (400MHz, CDCl3): δ7.35–7.29(m,5H),5.96(dd,J=14.3,8.3Hz,1H),5.10(s,2H),4.61–4.40(m,2H),3.85–3.68(m,2H),3.65–3.4 9(m,2H),3.41(d,J=12.7Hz,1H),3.31(s,1H),1.95(qdd,J=15.0,11.8,5.3Hz,2H),1.77(s,1H),0.86(s,9H),0.06(d,J=3.1Hz,6H).

[0094] 2.4 Preparation of intermediate 2-4

[0095]

[0096] Compound 2-3 (10.65mmol, 4.5g) was placed in a clean dry reaction bottle, 100mL of pyridine was added, and 4,4'-bismethoxytrityl chloride (1.2equiv, 12.78mmol, 4.32g) was added at room temperature, and then stirred at room temperature for 12 hours. After the reaction, 150mL of ethyl acetate was added to the reaction solution, and washed with 150mL of saturated sodium bicarbonate solution and 150mL of saturated brine, the organic phase was dried, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1-1 / 1) to obtain a light yellow oil compound 2-4 (7.56g, 10.43mmol, 98% yield). Compound 2-4 molecular formula: C 42 H 52 O7N2Si, molecular weight: 724.3, LC-MS measured: 747.4 (M+Na). 1 H NMR (400MHz, CDCl3): δ7.35–7.31(m,1H),7.28(d,J=4.7Hz,4H),7.27–7.23(m,2H),7.23–7.14(m,5H), 7.13–7.11(m,2H),6.80–6.78(m,1H),6.76(dd,J=7.7,5.4Hz,4H),5.72(dd,J=22.7,8.3Hz,1H),5.08– 4.99(m,2H),4.69–4.59(m,1H),4.35–4.30(m,1H),3.73(dd,J=4.5,3.7Hz,6H),3.65–3.44(m,2H),3.3 6–3.20(m,3H),1.86–1.81(m,1H),1.70(s,1H),0.80(d,J=13.1Hz,9H),-0.02(dd,J=14.9,4.2Hz,6H).

[0097] 2.5 Preparation of intermediate 2-5

[0098]

[0099] Compound 2-4 (10.43mmol, 7.56g) was placed in a clean dry reaction bottle, 100mL of methanol was added, palladium carbon (wet basis, 10% Pd / C) (10% wt, 750.0mg) was added under hydrogen at room temperature, and then stirred at room temperature for 12 hours. After the reaction, the palladium carbon was filtered off, and the filtrate was concentrated to obtain a crude product of white solid compound 2-5 (6.0g, 10.22mmol, 98% yield), which was directly used in the next step without purification. Compound 2-5 molecular formula: C 34 H 46 O5N2Si, molecular weight: 590.3, LC-MS measured: 591.6 (M+H).

[0100] 2.6 Preparation of intermediate 2-6

[0101]

[0102] Compound 5-(((2R,3R,4R,5R,6R)-3-acetylamino-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (commercially available, purchased from Noganlin Biopharmaceutical Technology (Suzhou) Co., Ltd.) (2.06 g, 4.62 mmol) was placed in a clean dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 6.93 mmol, 2.63 g) was added at room temperature and stirred for ten minutes. Subsequently, compound 2-5 (1.1 equiv, 5.08 mmol, 3.0 g) and N,N-diisopropylethylamine (3.0 equiv, 13.86 mmol, 17.91 g) were added to the reaction system, and then stirring was continued at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered and concentrated. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1-10 / 1) to obtain a white solid compound 2-6 (3.58 g, 3.51 mmol, 76% yield). Compound 2-6 molecular formula: C 53 H 73 O 15 N3Si, molecular weight: 1019.3, LC-MS measured: 1018.3 (MH).

[0103] 2.7 Preparation of intermediate 2-7

[0104]

[0105] Compound 2-6 (3.51mmol, 3.58g) was placed in a clean dry reaction bottle, 50mL of pyridine was added, and triethylamine hydrogen fluoride (5.0equiv, 17.55mmol, 2.97g) was added at room temperature, and then stirred at room temperature for 12 hours. After the reaction, 100mL of ethyl acetate was added to the reaction solution, and washed with 100mL of saturated sodium bicarbonate solution and 100mL of saturated brine, the organic phase was dried, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1-10 / 1) to obtain a light yellow oil compound 2-7 (2.4g, 2.65mmol, 76% yield). Compound 2-7 molecular formula: C 47 H 59 O 15 N3, molecular weight: 905.3, LC-MS measured: 904.4 (MH). 1H NMR (400MHz, CDCl3): δ7.30 (dd, J = 4.2, 1.9Hz, 1H), 7.29–7.25 (m, 5H), 7.19–7.15 (m, 4H), 6.85–6.81 (m, 4H), 5.40–5.34 (m, 1H), 5.30 (s, 1H), 5.26–5.19 (m, 1H), 5.13 (ddd, J = 14.5, 10.9, 3.3Hz, 1H), 4.85–4.78 (m, 1H), 4.75–4.71 (m, 1H), 4.68–4.61 (m, 1H), 4.50 (d, J=11.5Hz,1H),4.18–4.11(m,2H),4.06–3.97(m,1H),3.90(dt,J=10.6,6.8Hz,2H),3.80(s,6H),3.67–3.46(m,4H),3.25–3.19(m,2 H),2.34–2.23(m,1H),2.17–2.15(m,3H),2.10–2.03(m,5H),1.98(dt,J=12.9,2.4Hz,4H),1.76–1.61(m,4H),1.37(t,J=7.3Hz,3H).

[0106] 2.8 Preparation of Compound I-1-7

[0107]

[0108] Compound 2-7 (2.65mmol, 2.4g) was placed in a clean dry reaction bottle, and 50mL of anhydrous dichloromethane (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) was added. Compound 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (2.0equiv, 5.3mmol, 1.6g) and 4,5-dicyanoimidazole (1.5equiv, 3.97mmol, 470.0mg) were added under argon protection at room temperature, and stirring was continued for one hour at room temperature. After the reaction, 50mL of dichloromethane was added to the reaction solution, and it was washed with 100mL of saturated sodium bicarbonate solution. The organic phase was dried, filtered and concentrated, and the crude product was purified by C18 reverse phase column (specification: 30μm; Commercially available, purchased from Shanghai Boyun Biotechnology Co., Ltd.) (MeCN:H2O=75%:25%) to prepare white solid I-1-7 (2.03 g, 1.84 mmol, 70% yield). Compound I-1-7 molecular formula: C 56 H 76 O 15 N6P, molecular weight: 1105.5, LC-MS measured: 1128.4 (M+Na). 1 H NMR (400MHz, DMSO-d6): δ8.12–8.06(m,1H),7.78(dd,J=9.1,2.0Hz,1H),7.35–7.28(m,4H),7.23–7.17(m,5H),6.88(d,J=7.5Hz,4H),5.21(d,J =3.3Hz,1H),4.97(dd,J=11.2,3.0Hz,1H),4.86–4.75(m,1H),4.52(s,1 H),4.47(d,J=8.5Hz,1H),4.04–3.98(m,3H),3.91–3.83(m,1H),3.74(s ,6H),3.70–3.60(m,3H),3.58–3.47(m,3H),3.39(t,J=11.7Hz,2H),3.3 1(d,J=4.1Hz,1H),3.19(qd,J=8.7,3.8Hz,1H),3.02(dt,J=19.9,6.8Hz ,1H),2.78–2.70(m,1H),2.60(td,J=5.8,1.8Hz,1H),2.09(s,5H),1.98 (s,4H),1.89(s,3H),1.73(s,3H),1.44(s,4H),1.20–0.88(m,14H).31P NMR (162MHz, DMSO-d6): δ148.22 (s), 146.82 (t, J = 35.8Hz).

[0109] 2. Preparation of siRNA Conjugates

[0110] The solid phase phosphoramidite method was used to initiate the cycle using compound SA51 prepared in the above steps, and nucleoside monomers were connected one by one from the 3'-5' direction according to the nucleotide arrangement order. Each connection of a nucleoside monomer included four steps of deprotection, coupling, capping, oxidation or sulfurization. The same synthesis conditions were used for the sense chain and the antisense chain.

[0111] Instrument model: Biolytic Dr. Oligo 48 solid phase synthesizer, Biocomma Embed CPG Frits universal synthesis column DS0200, Biocomma 96-well plate desalting column DC189650 (80 mg). Table 1 shows the reagents used to synthesize siRNA conjugates.

[0112] Table 1

[0113]

[0114] The synthesis conditions are as follows:

[0115] The nucleoside monomer was provided in an acetonitrile solution with a concentration of 0.05 M. The conditions for the deprotection reaction in each step were the same, namely, the temperature was 25° C., the reaction time was 3 minutes, the deprotection reagent was DCA, and the injection volume was 180 μL.

[0116] The reaction conditions for each coupling step were the same, including a temperature of 25°C, a reaction time of 3 minutes, a nucleoside monomer injection volume of 90 μL, and a catalyst ACT injection volume of 110 μL.

[0117] The capping conditions were the same for each step, including a temperature of 25°C and a reaction time of 2 minutes. The capping reagent solution was a mixed solution of CapA and CapB (CapB1:CapB2=1:1) at a molar ratio of 1:1. The capping reagent injection volume was 180 μL.

[0118] The oxidation reaction conditions were the same in each step, including a temperature of 25°C, a reaction time of 3 minutes, and an injection volume of 180 μL of the oxidation reagent OXD.

[0119] The reaction conditions for each step of the sulfurization reaction were the same, including a temperature of 25°C, a reaction time of 4 minutes, and a sulfurization reagent of 0.05 M PADS in pyridine acetonitrile. The injection volume of the sulfurization reagent was 180 μL.

[0120] After the last nucleoside monomer is connected, the nucleic acid sequence connected to the solid phase carrier is cut, deprotected, purified, desalted, and then freeze-dried to obtain the sense chain and the antisense chain, wherein:

[0121] The cleavage and deprotection conditions are as follows: the synthesized nucleotide sequence connected to the vector is added to a mixed solution of ammonia water: ethanol = 3:1 to a volume of 0.8 mL, reacted at 50°C for 15 hours, filtered to remove the remaining vector, and the supernatant was vacuum concentrated to dryness.

[0122] Purification and desalting conditions are as follows: Desalting is performed using a C18 reverse phase column. Specific conditions include:

[0123] (1) Sample preparation

[0124] 0.1 M TEAA (triethylamine acetate) was added to the oligonucleotide sample to a volume of 0.8 mL.

[0125] (2) Activation of 96-well plates

[0126] Activation: 0.8 mL of acetonitrile was passed through each well of a 96-well plate for activation;

[0127] Equilibration: The 96-well plate was equilibrated with 0.8 mL of TEAA (pH 7.0) solution.

[0128] (3) The purification process is carried out in the following order:

[0129] Pass 0.8 mL of the solution containing the oligonucleotide through a desalting column;

[0130] Wash the 96-well plate twice with 0.8 mL of 6.5% ammonia to remove failed sequences;

[0131] Rinse the 96-well plate twice with 0.8 mL of deionized water to remove salt;

[0132] The 96-well plate was washed three times with 0.8 mL of 3% trifluoroacetic acid to remove DMT, and the adsorbed layer was observed to turn orange-red;

[0133] Wash the 96-well plate with 0.8 mL of 0.1 M TEAA;

[0134] The 96-well plate was rinsed twice with 0.8 mL of deionized water to remove trifluoroacetic acid and residual salt;

[0135] Elution was performed with 0.6 mL of 20% acetonitrile and the resulting product was collected and lyophilized.

[0136] The detection method is as follows: Waters Acquity UPLC-LTQ LCMS (column: ACQUITY UPLC BEHC18) is used to detect the purity of the sense chain and antisense chain and analyze the molecular weight. The measured values ​​are consistent with the theoretical values, indicating that the synthesized sense chain and antisense chain are conjugated with groups at the 3' end and / or 5' end.

[0137] Annealing operation is as follows: dissolve the sense strand and antisense strand synthesized in step 2 in water for injection, prepare 0.1mg / mL-40mg / mL solution, calibrate the mixture in equal molar ratio using a concentration meter, heat at 90°C for 5 minutes, and then slowly cool down naturally to form a double-stranded structure through hydrogen bonding, take samples and send to detect the SEC purity of the product. The double-stranded sample is freeze-dried.

[0138] Example 3 Synthesis of Ago monomer, Cgo monomer, and Ugo monomer and preparation of siRNA modified with the monomers

[0139] 3.1. The synthesis route of Ago monomer refers to Example 2 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows:

[0140]

[0141] (1) Dissolve anhydrous diisopropylamine (16.2 g, 160.0 mmol, 22.6 mL, 2.0 equiv) in 350 mL of anhydrous tetrahydrofuran, cool to -70°C to -78°C, replace with nitrogen, and drop n-butyl lithium solution (2.5 M, 67.1 mL) (slowly drop, the drop process lasts at least 10 minutes), and continue to stir the reaction solution at -70°C to -78°C for half an hour. Dissolve compound 1 (9.44 g, 79.9 mmol, 9.17 mL, 1.0 equiv) in 175 mL of anhydrous tetrahydrofuran, cool to -70°C to -78°C, and replace with nitrogen, and drop the solution obtained in the previous step (slowly drop, the drop process lasts at least 10 minutes). The reaction solution continues to stir at -70°C to -78°C for half an hour. Maintaining the previous temperature, hexamethylphosphoric acid triamide (26.1g, 146mmol, 25.6mL, 1.82equiv) and benzyl chloromethyl ether (17.5g, 112mmol, 15.5mL, 1.4equiv) were slowly added to the previous reaction solution (slowly added, the addition process lasted for at least 10 minutes). After the addition was completed, the temperature was raised to 0°C and stirred for 3 hours. TLC and LCMS detected that compound 1 disappeared. 600mL of saturated ammonium chloride solution was added in two batches to quench the reaction, and the mixture was extracted with 200mL of methyl tert-butyl ether. The organic phase was collected, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 1 / 1) to obtain a light brown compound 2 (9.69g, 40.7mmol, 51% yield). 1H NMR (400MHz, CDCl3): δ7.46-7.28(m,10H),4.58-4.46(m,2H),4.19-4.08(m, 1H),3.82-3.67(m,5H),2.77(q,J=6.1Hz,1H),1.24(d,J=6.5Hz,4H).LC-MS:C 13 H 18 O4, molecular weight 238.1, 239.1 (M+H).

[0142] (2) Compound 2 (14.7 g, 61.7 mmol, 1.0 equiv) was dissolved in 150 mL of dichloromethane, and under nitrogen protection, imidazole (16.8 g, 247.0 mmol, 4.0 equiv) and tert-butyldimethylsilyl chloride (27.9 g, 185.0 mmol, 22.7 mL, 3.0 equiv) were added at room temperature. The reaction solution was stirred at room temperature for one hour, and TLC and LCMS detection showed that compound 2 disappeared. 100 mL of dichloromethane was added to the reaction solution, and the reaction solution was washed twice with 400 mL of saturated brine. The organic phase was dried, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain a light yellow oil compound 3 (12.0 g, 34.0 mmol, 55% yield). 1 H NMR (400MHz, CDCl3): δ7.40-7.25(m,5H),4.52(d,J=2.4Hz,2H),4.10(t,J=6.3Hz,1H),3.75-3.65(m,4H),3.59(dd ,J=9.2,5.3Hz,1H),2.79(dt,J=8.4,5.9Hz,1H),1.17(d,J=6.2Hz,3H),0.86(s,9H),0.04(d,J=8.6Hz,6H).LC-MS:C 19 H 32 O4Si, molecular weight 352.1, 353.2 (M+H).

[0143] (3) Compound 3 (11.1 g, 31.5 mmol, 1.0 equiv) was dissolved in tetrahydrofuran, cooled to between -70°C and -60°C, and diisobutylaluminum hydride (1.0 M, 69.3 mL, 2.2 equiv) was added dropwise under nitrogen protection. Stirring was continued at this temperature for two hours. LCMS detection showed that compound 3 disappeared. The temperature was raised to 0°C, 20 mL of ethyl acetate was added, and then 100 mL of potassium sodium tartrate solution was used to quench the reaction, and stirring was continued for half an hour. The mixture was washed with 100 mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a light yellow oil compound 4 (9.75 g, 30.0 mmol, 95% yield). 1 H NMR (400MHz, CDCl3): δ7.40-7.27(m,5H),4.59-4.45(m,2H),4.19(dd,J=6.2,3.7Hz,1H),4.01(dd,J=11.3,4.0 Hz,1H),3.78-3.60(m,3H),1.78-1.68(m,1H),1.29-1.21(m,3H),0.95-0.87(m,9H),0.12-0.02(m,6H).LC-MS:C 18 H 32 O3Si, molecular weight 324.1, 325.2 (M+H).

[0144] (4) Compound 4 (9.75 g, 30.0 mmol, 1.0 equiv) was dissolved in tetrahydrofuran, cooled to 0°C, and p-toluenesulfonyl chloride (11.5 g, 60.1 mmol, 2.0 equiv) and methylimidazole (6.17 g, 75.1 mmol, 5.99 mL, 2.5 equiv) were added dropwise under nitrogen protection. After the addition was completed, the temperature was raised to room temperature and stirring was continued for 16 hours. LCMS detection showed that compound 4 disappeared. 20 mL of ethyl acetate was added to the reaction solution, and the reaction was quenched with 100 mL of potassium sodium tartrate solution under ice bath, and stirring was continued for half an hour. The mixture was washed with 100 mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product of light yellow oily compound 5 (13.7 g, 28.6 mmol, 95% yield). 1H NMR (400MHz, CDCl3): δ7.89-7.68(m,2H),7.42-7.17(m,10H),4.47-4.33(m,2H),4.23(dd,J=9.6,5.1Hz,1H),4.13-4.06(m,1H),4. 01-3.94(m,1H),3.52-3.34(m,2H),2.43(s,3H),2.02-1.89(m,1H),1.10(d,J=6.3Hz,3H),0.81(s,8H),0.04--0.05(m,6H).LC-MS:C 25 H 38 O5SSi, molecular weight 478.1, 479.2 (M+H).

[0145] (5) Under nitrogen protection, compound 5 (13.7 g, 28.6 mmol, 1.0 equiv) and 35 mL of acetonitrile were added to a dry reaction bottle, and the acetonitrile was evaporated at 35-40°C to remove the water in compound 5. Under nitrogen protection, 80 mL of N,N-dimethylformamide, compound 5-1 (9H-purin-6-amine) (4.25 g, 31.5 mmol, 1.1 equiv) and potassium carbonate (3.96 g, 28.6 mmol, 1.0 equiv) were added to another clean and dry reaction bottle, and the temperature was raised to 95-100°C and stirred for half an hour. At this temperature, a solution of compound 5 (13.7 g, 28.6 mmol, 1.0 equiv) in N,N-dimethylformamide (60 mL) was added dropwise to the reaction solution, and stirring was continued for 12 hours. LCMS detection showed that compound 5 disappeared. The reaction solution was cooled to room temperature, 200 mL of ethyl acetate was added, and the mixed solution was washed with 200 mL of sodium bicarbonate solution and 100 mL of saturated brine in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give a light yellow oily compound 6 (6.2 g, 14.0 mmol, 49% yield). 1 H NMR (400MHz, CDCl3): δ8.37(s,1H),7.75(s,1H),7.39-7.24(m,6H),5.66(br,s,2H),4.47-4.34(m,3H),4.21(dd,J=14.1,8.8Hz,1H), 4.07(dd,J=6.2,4.9Hz,1H),3.42-3.34(m,2H),2.10-1.96(m,1H),1.19(d,J=6.4Hz,3H),0.90(s,9H),0.06(d,J=6.0Hz,6H).LC-MS:C 23 H 35N5O2Si, molecular weight 441.1, 442.3 (M+H).

[0146] (6) Palladium carbon (3.0 g, 10% purity) was dissolved in 25 mL of methanol at room temperature, and 25 mL of compound 6 (5.2 g, 11.8 mmol, 1.0 equiv) methanol solution and trifluoroacetic acid (134.0 mg, 1.18 mmol, 87.2 uL) were added. The reaction solution was stirred under 50 psi hydrogen pressure for 48 hours. LCMS detection showed that compound 6 disappeared. The reaction solution was filtered and concentrated to obtain a crude product of light yellow oil compound 7 (3.9 g, 11.1 mmol). 1 H NMR (400MHz, CDCl3): δ8.21(s,1H),8.12(s,1H),4.50-4.36(m,1H),4.33-4.22(m,1H),4.15-4.02(m,1H),3 .53(d,J=5.9Hz,2H),2.21-2.09(m,1H),1.25(d,J=6.4Hz,3H),0.88(s,9H),0.05(d,J=3.1Hz,6H).LC-MS:C 16 H 29 N5O2Si, molecular weight 351.1, 352.2 (M+1).

[0147] (7) Compound 7 (3.9 g, 11.1 mmol, 1.0 equiv) was placed in a clean dry reaction bottle, 10 mL of pyridine was added under nitrogen protection, the temperature was raised to evaporate the pyridine, and this operation was repeated once to remove the water in compound 7. 28 mL of pyridine was added, trimethylsilyl chloride (4.8 g, 44.4 mmol, 5.63 mL, 4.0 equiv) was added under ice bath, the temperature was raised to room temperature, and stirring was continued for two hours. TLC detection showed that compound 7 disappeared. Benzoyl chloride (6.2 g, 44.4 mmol, 5.15 mL, 4.0 equiv) was added under ice bath, and stirring was continued for 2 hours. TLC detection showed that the raw material reaction disappeared. 60 mL of water and 90 mL of concentrated ammonia were added dropwise and stirring was continued for half an hour. The reaction solution was extracted with 250 mL of ethyl acetate, and the organic phase was washed with saturated brine, dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (elution system: dichloromethane / methanol = 50 / 1 to 10 / 1) to obtain a light yellow oil compound 8 (4.0 g, 8.78 mmol, 79% yield). 1H NMR (400MHz, CDCl3): δ9.22-8.90(m,1H),8.79(s,1H),8.07-8.04(m,2H),8.03(d,J=1.4 Hz,1H),7.65-7.59(m,1H),7.57-7.50(m,2H),4.62-4.50(m,1H),4.42(dd,J=14.3,8.6Hz ,1H),4.24-4.09(m,1H),4.05(d,J=6.3Hz,1H),3.59-3.48(m,1H),3.47-3.35(m,1H),2.0 4-1.98(m,1H),1.31(d,J=6.3Hz,3H),0.98-0.84(m,9H),0.11(d,J=10.1Hz,5H).LC-MS:C 23 H 33 N5O3Si, molecular weight 455.2,456.3 (M+H).

[0148] (8) Compound 8 (4.0 g, 8.78 mmol, 1.0 equiv) was placed in a clean dry reaction bottle, 10 mL of pyridine was added under nitrogen protection, the pyridine was evaporated by heating, and this operation was repeated once to remove the water in compound 8. 28 mL of pyridine was added, and 4,4'-bismethoxytrityl chloride (3.27 g, 9.66 mmol, 1.1 equiv) was added under ice bath, and the mixture was heated to room temperature and stirred for 1 hour. TLC detection showed that compound 8 disappeared. 150 mL of ethyl acetate was added to the reaction mixture, and the mixture was washed with 200 mL of sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered and the filtrate was concentrated. The crude product was separated and purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain a light yellow oil compound 9 (5.91 g, 7.8 mmol, 88% yield). 1H NMR (400MHz, CDCl3): δ9.07 (br s,1H),8.82(s,1H),8.04(d,J=7.1Hz,2H),7.80(s,1H),7.65-7.58(m,1H),7.57-7.50(m,2H),7. 28-7.13(m,9H),6.81-6.69(m,4H),4.52-4.43(m,1H),4.25(dd,J=14.2,8.6Hz,1H),4.07(dd,J=6 .3,4.2Hz,1H),3.76(d,J=4.5Hz,6H),3.22(dd,J=9.8,5.4Hz,1H),3.04(dd,J=9.8,6.1Hz,1H),2 .34(dd,J=8.1,4.5Hz,1H),1.19(d,J=6.3Hz,3H),0.90-0.77(m,9H),0.07--0.09(m,6H).LC-MS:C 44 H 51 N5O5Si, molecular weight 757.3,758.4 (M+H).

[0149] (9) Compound 9 (3.00 g, 3.96 mmol, 1.0 equiv) was dissolved in tetrahydrofuran, and pyridinium hydrofluoride (2.26 g, 79.2 mmol, 2.1 mL, 20.0 equiv) and imidazole (10.8 g, 158.0 mmol, 40.0 equiv) were added under nitrogen protection and ice bath. The temperature was raised to room temperature and stirring was continued for 2 hours. LCMS detection showed that compound 9 disappeared. 50 mL of ethyl acetate was added, and the mixture was washed with 100 mL of sodium bicarbonate solution and 50 mL of saturated brine, dried and filtered, and the filtrate was concentrated. The crude product was separated and purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain a light yellow oil compound 10 (2.44 g, 3.79 mmol, 96% yield). 1H NMR (400MHz, DMSO-d6): δ11.16 (br s,1H),8.70(s,1H),8.33(s,1H),8.05(d,J=7.4Hz,2H),7.69-7.61(m,1H),7.60-7.52( m,2H),7.25-7.12(m,5H),7.05(t,J=8.9Hz,4H),6.78(dd,J=8.9,3.1Hz,4H),4.79(d,J =4.0Hz,1H),4.51-4.28(m,2H),3.81(d,J=4.0Hz,1H),3.70(s,6H),3.10(dd,J=9.8,4. 9Hz,1H),2.89(dd,J=9.7,5.1Hz,1H),2.37-2.23(m,1H),1.03(d,J=6.3Hz,3H).LC-MS:C 38 H 37 N5O5, molecular weight 643.2, 644.2 (M+H).

[0150] (10) Compound 10 (1.5 g, 2.33 mmol, 1.0 equiv) was placed in a clean dry reaction bottle, 4 mL of acetonitrile was added under nitrogen protection, the temperature was raised to 35-40 °C to evaporate the acetonitrile, and this operation was repeated once to remove the water in compound 10. 15 mL of anhydrous dichloromethane was added to the above reaction bottle at room temperature. Compound 11-1 (1.05 g, 3.5 mmol, 1.11 mL, 1.5 equiv) and 4,5-dicyanoimidazole (358 mg, 3.03 mmol, 1.3 equiv) were added, and stirring was continued at room temperature for one hour. TLC detection showed that compound 10 disappeared. 30 mL of dichloromethane was added, and the mixture was washed with sodium bicarbonate solution (50 mL x 2) and saturated brine (50 mL). The organic phase was dried, filtered and the filtrate was concentrated. The crude product was dissolved in 50 mL of methyl tert-butyl ether, and 100 mL of 1% sodium hydroxide aqueous solution was added and stirred for half an hour. The organic phase was collected after standing and stratified, washed with saturated brine, dried, filtered and concentrated, and the crude product was purified by C18 reverse phase column to obtain a light yellow product SA000001 (1.1 g, 1.3 mmol, 56% yield). 1HNMR(400MHz,CD3CN): δ9.33(br s,1H),8.61(br s,1H),7.99(d,J=11.0Hz,3H),7.67-7.60(m,1H),7.59-7.49(m,2H),7.32-6.99(m,9H), 6.75(td,J=9.2,6.5Hz,4H),4.50-4.38(m,1H),4.36-4.13(m,2H),3.72(dd,J=4.8,1.5H z,6H),3.66-3.45(m,3H),3.25(td,J=9.6,5.4Hz,1H),3.01(ddd,J=17.9,10.0,5.8Hz,1 H),2.62(t,J=5.9Hz,1H),2.53(t,J=5.9Hz,1H),1.32-1.22(m,4H),1.17-1.05(m,12H). 31 P NMR(DMSO-d6,162MHz): δppm 147.7,146.8.LCMS:C 47 H 54 N7O6P, molecular weight 843.3, 844.5 (M+H).

[0151] 3.2. The synthesis route of Cgo monomer refers to Example 4 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows:

[0152]

[0153] (1) Compound 3-2 (8.5 g, 20.3 mmol, prepared by Example 5) and 1,2,4-triazole (19.5 g, 282.0 mmol, 13.9 equiv) were dissolved in pyridine (128.0 mL) at room temperature, and then 4-chlorophenyl dichlorophosphate (56.9 mmol, 9.25 mL, 2.8 equiv) was added dropwise to the reaction system in an ice-water bath. The reaction solution was stirred at 30°C for 16 hours. After the reaction was completed, the solvent pyridine was distilled off under reduced pressure, and the remaining system was extracted with water and ethyl acetate for 3 times. The organic phases were combined and dried to obtain a crude yellow oily product, compound C-1 (9.5 g), which was directly used in the next step. Mass spectrometric identification of compound C-1 (C 24 H 35 N5O3Si, molecular weight 469.1, [M+H] = 470.3).

[0154] (2) Compound C-1 (9.5 g, 20.2 mmol) was dissolved in 1,4-dioxane (95.0 mL) at room temperature, and then aqueous ammonia (1.38 mol, 212.1 mL, 25% purity, 68.0 equiv) was added to the reaction system. The reaction solution was stirred at 30°C for 16 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the remaining system was extracted with water and dichloromethane for 3 times. The organic phases were combined and dried to obtain a crude yellow solid compound C-2 (8.5 g), which was directly used in the next step. Mass spectrometry identification of compound C-2 (C 22 H 35 N3O3Si, molecular weight 417.1, [M+H] = 418.2).

[0155] (3) Compound C-2 (8.5 g, 20.2 mmol) was dissolved in N,N-dimethylformamide (85.0 mL) at room temperature, and then acetic anhydride (3.1 g, 30.4 mmol, 2.85 mL, 1.5 equiv) was slowly added to the reaction system. The reaction solution was stirred at 30°C for 3 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the remaining system was extracted with saturated sodium bicarbonate solution and ethyl acetate for 3 times. The organic phases were combined and dried by spin drying. The crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol 1:0 to 100:1) to obtain a yellow solid compound C-3 (4.2 g, reaction yield 43%). 1 H NMR data: (400MHz, DMSO-d6) δ10.7 (s, 1H), 7.79 (d, J = 7.2Hz, 1H), 7.29 (m, 5H), 7.08 (d, J = 7.2Hz, 1H), 4.36 (d, J = 1.2Hz, 2H), 4.05-3.99 (m, 2H), 3.72-3.67 (m, 1H), 3.39 (dd, J = 6.4Hz, 2H), 2.15-2.08 (m, 1H), 2.08 (s, 3H), 1.15 (d, J = 6.4Hz, 3H), 0.85 (s, 9H), 0.02 (d, J = 6.8Hz, 6H). Mass spectrometry identification of compound C-3 (C 24 H 37 N3O4Si, molecular weight 459.1, [M+H] = 460.2).

[0156] (4) Compound C-3 (4.3 g, 9.35 mmol) was dissolved in dichloromethane (46.0 mL) at -78 °C, and then boron trichloride (1.0 M in DCM, 46.8 mL, 5.0 equiv) was slowly added to the reaction system. The reaction solution was then stirred at -78 °C for 4 hours. After the reaction was completed, triethylamine (40.0 mL) and methanol (88.0 mL) were used to quench the reaction. The remaining system was extracted with water and dichloromethane for 3 times. The organic phases were combined and dried by rotation. The crude product was used to prepare a white solid compound C-4 (0.96 g, reaction yield 40%) using a C18 reverse phase column. 1 H NMR data: (400MHz, DMSO-d6) δ10.7 (s, 1H), 8.01 (d, J = 7.2Hz, 1H), 7.12 (d, J = 7.2Hz, 1H), 4.60 (d, J = 4.8Hz, 2H), 4.53-4.50 (m, 1H), 4.00-3.99 (m, 1H), 3.75-3.70 (m, 2H), 3.37-3.32 (m, 2H), 2.08 (s, 3H), 1.81-1.77 (m, 1H), 1.01 (d, J = 6.4Hz, 3H). Mass spectral identification of compound C-4 (C 11 H 17 N3O4, molecular weight 255.1, [M+H] = 256.2).

[0157] (5) Compound C-4 (1.5 g, 5.88 mmol) was dissolved in pyridine (10.0 mL) at room temperature, and 4,4'-bismethoxytrityl chloride (2.4 g, 7.05 mmol, 1.2 equiv) was added to the reaction system under ice-water bath conditions. The reaction solution was then stirred at room temperature for 4 hours. After the reaction was completed, the solvent pyridine was removed by distillation under reduced pressure, and the remaining system was extracted with saturated sodium bicarbonate solution and ethyl acetate for 3 times. The organic phases were combined and spin-dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 4:1 to 0:1) to obtain a white solid compound C-5 (0.7 g, reaction yield 70%). 1H NMR data: (400MHz, CDCl3) δ9.71 (s, 1H), 7.39 (d, J = 7.3Hz, 3H), 7.35-7.21 (m, 7H) ,7.06(d,J=7.1Hz,1H),6.85(d,J=8.8Hz,4H),4.71(d,J=3.3Hz,1H),4.43(dd,J =13.8,4.5Hz,1H),4.23-3.99(m,2H),3.80(s,6H),3.50-3.38(m,1H),3.31(dd ,J=10.0,4.1Hz,1H),2.69(t,J=9.4Hz,1H),2.21(s,3H),1.08(d,J=6.1Hz,3H). Mass spectrometry identification of compound C-5 (C 32 H 35 N3O6, molecular weight 557.1, [M+H] = 558.4).

[0158] (6) Compound C-5 (2.0 g, 3.59 mmol) was dissolved in dichloromethane (20.0 mL) under nitrogen conditions at room temperature, and 4,5-dicyanoimidazole (466.0 mg, 3.95 mmol, 1.1 equiv) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.4 g, 4.66 mmol, 1.48 mL, 1.3 equiv) were added to the reaction system respectively. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was dissolved in methyl tert-butyl ether (10.0 mL) and 1% sodium hydroxide solution (10.0 mL), and continued to stir at room temperature for 0.5 hours. The remaining system was extracted with saturated sodium bicarbonate solution and dichloromethane for 3 times, the organic phases were combined and spin-dried, and the crude product was prepared using a C18 reverse phase column to obtain a white solid compound SA000015 (1.5 g, reaction yield 55%). Compound SA000015 1 H NMR data: (400 MHz, CD3CN) δ9.15 (s, 1H), 7.50-7.18 (m, 11H), 6.84-6.80 (m, 4H), 4.22-4.08 (m, 2H), 3.75-3.22 (m, 11H), 3.23-3.22 (m, 2H), 2.62-2.51 (m, 2H), 2.38-2.35 (m, 1H), 2.12 (s, 3H), 1.022-1.07 (m, 15H). 31 P NMR data: (400MHz, CD3CN) δ147.5,146.7. Mass spectrometry identification of compound SA000015 (C 41 H 52 N5O7P, molecular weight 757.1, [M+H] = 758.5).

[0159] 3.3. The synthesis route of Ugo monomer refers to Example 5 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows:

[0160]

[0161] (1) Compound 1-4 (9.99 g, 30.8 mmol), compound U-1 (commercially available, purchased from Shanghai Haohong Biopharmaceutical Technology Co., Ltd.) (9.33 g, 43.1 mmol, 1.4 equiv) and triphenylphosphine (16.6 g, 63.2 mmol, 2.0 equiv) were dissolved in dry tetrahydrofuran (350.0 mL) in an ice-water bath, and diisopropyl azodicarboxylate (13.1 g, 64.7 mmol, 12.6 mL, 2.1 equiv) was then added dropwise to the reaction system. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was extracted three times with saturated sodium bicarbonate solution and ethyl acetate, the organic phases were combined and spin-dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 10:1 to 8:1) to obtain a white solid compound 3-1 (16.1 g, reaction yield 99%). Compound 3-1 1 H NMR data: (400MHz, DMSO-d6) δ7.89-7.74 (m, 4H), 7.56-7.53 (m, 2H), 7.33-7.29 (m, 5H), 5.80-5.73 (m, 1H), 4.46-4.38 (m, 2H), 4.00-3.91 (m, 2H), 3.60-3.50 (m, 1H), 3.49-3.43 (m, 2H) 2.17-1.98 (m, 1H), 1.13 (s, 3H), 0.83 (s, 9H), 0.01 (d, J = 6.0 Hz, 6H). Mass spectrometry identification of compound 3-1 (C 29 H 38 N2O5Si, molecular weight 522.1, [M+H] = 523.2).

[0162] (2) Compound 3-1 (8.05 g, 15.4 mmol) was dissolved in methanol (160.0 mL) at room temperature, and then sodium methoxide (2.77 g, 15.4 mmol, 30% purity, 1.0 equiv) was slowly added to the reaction system. The reaction solution was then stirred at room temperature for 12 hours. After the reaction was completed, the solvent methanol was removed by distillation under reduced pressure, and the remaining system was extracted with 1M hydrochloric acid solution and ethyl acetate for 3 times. The organic phases were combined and spin-dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 10:1 to 0:1) to obtain a white solid compound 3-2 (6.1 g, reaction yield 94%). Compound 3-2 1 H NMR data: (400MHz, DMSO-d6) δ11.1 (s, 1H), 7.48 (d, J = 8.0Hz, 1H), 7.30-7.24 (m, 5H), 5.47-5.44 (m, 1H), 4.45-4.35 (m, 2H), 3.98-3.94 (m, 1H), 3.79-3.78 (m, 1H), 3.63-3.57 (m, 1H), 3.38-3.35 (m, 2H), 2.04-1.95 (m, 1H), 1.10 (s, 3H), 0.83 (s, 9H), 0.01 (d, J = 6.0Hz, 6H). Mass spectrometry identification of compound 3-2 (C 22 H 34 N2O4Si, molecular weight 418.1, [M+H] = 418.2).

[0163] (3) Compound 3-2 (4.0 g, 9.56 mmol) was dissolved in dichloromethane (30.0 mL) at -70 °C, and then boron trichloride (1.0 M in DCM, 66.9 mL, 7.0 equiv) was slowly added to the reaction system. The reaction solution was then stirred at -70 °C for 3 hours. After the reaction was completed, triethylamine (5.0 mL) and methanol (30.0 mL) were used to quench the reaction. The remaining system was extracted with water and dichloromethane for 3 times. The organic phases were combined and dried by rotation. The crude product was used to prepare a white solid compound 3-3 (0.7 g, reaction yield 33%) using a C18 reverse phase column. 1 H NMR data: (400MHz, DMSO-d6) δ7.54 (d, J = 8.0 Hz, 1H), 5.51 (d, J = 7.6 Hz, 1H), 3.88-3.84 (m, 1H), 3.72-3.70 (m, 1H), 3.61-3.59 (m, 2H), 1.75-1.68 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H). Mass spectrometry identification of compound 3-3 (C9H 14N2O4, molecular weight 214.1, [M+H] = 215.2).

[0164] (4) Compound 3-1 (0.4 g, 1.87 mmol) was dissolved in pyridine (4.0 mL) at room temperature, and 4,4'-bismethoxytrityl chloride (949.0 mg, 2.8 mmol, 1.5 equiv) was added to the reaction system under ice-water bath conditions. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the solvent pyridine was removed by distillation under reduced pressure, and the remaining system was extracted with saturated sodium bicarbonate solution and ethyl acetate for 3 times. The organic phases were combined and dried by spin drying. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 4:1 to 0:1) to obtain a white solid compound 3-4 (0.7 g, reaction yield 70%). Compound 3-4 1 H NMR data: (400MHz, DMSO-d6) δ11.3 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.33-7.29 (m, 4H), 7.20-7.17 (m, 5H), 6.86-6.83 (m, 4H), 5.40 (d, J = 8.0 Hz, 1H), 4.61 (d, J = 4.8 Hz, 2H), 3.83-3.79 (m, 2H), 3.72 (s, 6H), 3.71-3.68 (m, 1H), 3.08-2.90 (m, 2H), 1.90 (s, 1H), 1.01 (d, J = 6.4 Hz, 3H). Mass spectrometry identification of compound 3-4 (C 30 H 32 N2O6, molecular weight 516.1, [M+H] = 517.4).

[0165] (5) Compound 3-4 (1.2 g, 2.32 mmol) was dissolved in dichloromethane (12.0 mL) under nitrogen conditions at room temperature, and 4,5-dicyanoimidazole (357.0 mg, 3.02 mmol, 1.3 equiv) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.05 g, 3.48 mmol, 1.5 equiv) were added to the reaction system respectively. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was dissolved in methyl tert-butyl ether (10.0 mL) and 1% sodium hydroxide solution (10.0 mL), and continued to stir at room temperature for 0.5 hours. The remaining system was extracted with ethyl acetate for 3 times, the organic phases were combined and dried, and the crude product was used to prepare a white solid compound SA000016 (1.2 g, reaction yield 71%) using a C18 reverse phase column. Compound SA000016 1H NMR data: (400 MHz, CD3CN) δ9.39 (s, 1H), 7.39-7.24 (m, 10H), 6.85-6.81 (m, 4H), 5.43-5.39 (m, 1H), 4.21-4.18 (m, 1H), 3.86-3.77 (m, 1H), 3.75 (s, 6H), 3.56-3.53 (m, 5H), 3.28-3.05 (m, 2H), 2.62-2.61 (m, 2H), 2.22-2.19 (m, 2H), 1.22-1.07 (m, 15H). 31 P NMR data: (400MHz, CD3CN) δ147.6,146.5. Mass spectrometry identification of compound SA000016 (C 39 H 49 N4O7P, molecular weight 716.1, [M+H] = 717.5).

[0166] 3.4 Preparation of modified siRNA

[0167] The nucleotide position at the 6th or 7th position of the 5' region of the antisense strand contains a chemical modification represented by Ago, Cgo, or Ugo. The modified siRNA is obtained by solid phase synthesis according to Example 2.

[0168] The inventors designed and synthesized a large number of PD-L1 siRNAs in the early stage, and verified the cell activity, eliminated some PD-L1 siRNAs with poor effects, and retained some PD-L1 siRNAs with good activity for further experiments. The specific sequences are shown in Tables 2 to 4 below.

[0169] Table 2 below shows the unmodified sense strand and antisense strand of PD-L1 siRNA, Table 3 below shows the modified sense strand and antisense strand of PD-L1 siRNA (the table is the modified sequence corresponding to each siRNA in Table 1 from top to bottom), and Table 4 below shows the siRNA conjugate sequence. Among them, capital letters A, C, G, and U represent adenosine-3'-phosphate, cytidine-3'-phosphate, guanosine-3'-phosphate, and uridine-3'-phosphate, respectively; lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a 2'-methoxy-modified nucleotide; lowercase letter f indicates that the nucleotide adjacent to the left is a 2'-fluoro-modified nucleotide; lowercase letter s in the middle of the capital letter indicates that the two nucleotides adjacent to the left and right of s are linked by thiophosphate groups; s is the first at the 3' end, indicating that the terminal of a nucleotide adjacent to the left of the letter s is a thiophosphate group. The synthesis of SA51 and the synthesis of the conjugate are shown in Example 2.

[0170] Table 2

[0171]

[0172] Table 3

[0173]

[0174]

[0175]

[0176] Table 4

[0177]

[0178]

[0179] Example 4 IC50 in vitro screening: Dual luciferase assay

[0180] In vitro use The activity of siRNA targeting PD-L1 was tested by dual luciferase assay. The final concentration of siRNA for initial transfection was 10 nM, and compounds with less than 35% remaining activity at 10 nM were screened for activity at two concentrations, 1 nM and 0.2 nM, and IC50 screening was performed on the preferred compounds screened at two concentrations.

[0181] 1) Cell culture and plasmid / siRNA co-transfection

[0182] HEK293 cells were cultured in DMEM high glucose medium (Gibco, C11995500BT) with 10% fetal bovine serum at 37°C and 5% CO2, grown to a confluence of about 90%, and then digested with trypsin (Thermo, 25200072) and resuspended. The complete human PD-L1 reference sequence (NM_014143.4) was cloned into the dual-luciferase psiCHECK2TM vector multi-cloning sites XhoI and NotI to construct the hs-psiCHECK plasmid. The dual-luciferase plasmid was co-transfected with siRNA into 1x10 4cells. Using a 96-well plate, 0.3 μL of LipofectamineTM2000 was added to 19.7 μL Opti-MEM (Gibco, 31985070) containing 20 ng of plasmid vector and siRNA per well, and incubated at room temperature for 15 minutes, and the mixture was added to the 96 plate. Then, cells resuspended in 80 μL of fresh DMEM high-glucose medium (Gibco, C11995500BT) containing 10% fetal bovine serum were added. The cells were incubated for 24 hours and luciferase (Yishen Bio, 11405ES80) was detected.

[0183] 2) Dual luciferase assay

[0184] 24 hours after siRNA transfection, measure dual luciferase, i.e., firefly luciferase (internal reference) and Renilla luciferase (PD-L1 target sequence inserted after PolyA, fused into one mRNA). Referring to the product manual (Yisheng Bio, 11405ES80), first detect the luminescent signal of firefly luciferase on a multifunctional microplate reader (Bioteck, Synergy LX), and then detect the luminescent signal of Renilla luciferase. The detection order of Renilla luciferase on the microplate should be the same as that of firefly luciferase.

[0185] The Renilla luciferase signal readings in each well were normalized to the firefly luciferase (control) signal and then compared with cells transfected with the same plasmid but without siRNA treatment to assess the activity of each siRNA. All transfections were performed in duplicate.

[0186] The results are expressed as the remaining percentage relative to the control group without siRNA (the control group is 100%), and the data are shown in Table 5. As can be seen from Table 5, except for SD003798 and SD003955, the experimental results of other groups are better, and the siRNA with better effect is further studied.

[0187] Table 5

[0188] Compound No. Hs-psiCHECK IC50(nM) SD003141 0.0168 SD003143 0.0338 SD003187 0.0174 SD003189 0.0524 SD003223 0.0263 SD003765 0.0164 SD003798 0.2531 SD003842 0.0342 SD003844 0.0286 SD003887 0.0151 SD003955 0.2154

[0189] Example 5 siRNA activity in SNU-387 cells, IC50 screening in vitro

[0190] IC50 in vitro screening was performed in SNU-387 cells using 8 concentrations (starting from 10 nM and 3-fold dilutions, a total of 8 concentration points).

[0191] SNU-387 cells were cultured in RPMI-1640 medium (Thermo, 11875119) containing 10% fetal bovine serum at 37°C and 5% CO2, and then digested with trypsin and resuspended. siRNA was co-transfected into 2×10 4 cells. Using a 96-well plate, 0.3 μL of RNAiMAX was added to 19.7 μL Opti-MEM (Gibco, 31985070) containing different concentrations of siRNA in each well, and incubated at room temperature for 15 minutes. The mixture was added to the 96-well plate, and then the cells resuspended in 80 μL of fresh RPMI-1640 medium (Thermo, 11875119) containing 10% fetal bovine serum were added. The cells were incubated for 24 hours, RNA was extracted using a tissue cell extraction kit (Zhiang Bio, MNTR / FX96), reverse transcribed cDNA (Takara, 6210B), and the expression level of the PD-L1 gene was measured by SYBR Green qPCR (Vazyme, Q711). For specific operation methods, please refer to the corresponding instructions.

[0192] Target gene PD-L1 primers and probes:

[0193] Forward primer: TGCAGGGCATTCCAGAAAGAT (SEQ ID NO. 29);

[0194] Reverse primer: CCTTGGGAACCGTGACAGTA (SEQ ID NO. 30);

[0195] Primers for internal reference gene β-Actin:

[0196] Forward primer: TGCACCACCAACTGCTTAGC (SEQ ID NO. 31);

[0197] Reverse primer: ACTGTGGTCATGAGTCCTTCCA (SEQ ID NO. 32);

[0198] The relative levels at different concentrations were calculated compared with cells not treated with siRNA, and the IC50 values ​​were calculated. The results are shown in Tables 6 and Figure 1 The results showed that SD003141, SD003143, SD003187, SD003842, SD003844, and SD003887 had relatively good activities.

[0199] Table 6

[0200] Compound No. IC50(nM) Emax(%) SD003141 0.32 68.17 SD003143 0.53 72.72 SD003187 0.34 65.89 SD003189 3.66 57.75 SD003223 12.76 55.34 SD003765 19.35 52.04 SD003842 0.78 63.95 SD003844 0.94 57.36 SD003887 0.83 52.52

[0201] Example 6 In vitro on-target and off-target evaluation of siRNAs containing different chemical modifications

[0202] Dual luciferase reporter gene was used to detect the on-target and off-target activities of siRNAs with different chemical modifications.

[0203] HEK293 cells were cultured in DMEM high-glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2. Referring to the product manual, the reporter gene plasmid and siRNA of different concentrations (starting from a final concentration of 90nM, 3-fold dilution, a total of 11 concentrations) were co-transfected into the cells using Lipofectamine 2000 (ThermoFisher, 11668019). After 24 hours of transfection, the dual luciferase detection kit (Yishen Bio, 11405ES80) was used for detection. Sequences complementary to the antisense strand (on-target reporter plasmid) and five tandem sequences consistent with the 12-19 sites at the 5' end of the sense strand (off-target reporter plasmid) were inserted into the 3' untranslated region of the Renilla luciferase of the reporter plasmid. The reporter plasmids all contain firefly luciferase as an internal reference. The group transfected with only the plasmid was used as the control group. The Renilla luciferase signal readings of each well were normalized to the firefly luciferase (control) signal, and then compared with cells transfected with the same plasmid but not treated with siRNA to calculate the relative levels at different concentrations, and the IC50 values ​​were calculated, and the results are shown in Table 7. The results showed that modification of the nucleotides at the 6th or 7th position of the 5' region of the antisense strand in some sequences did not affect the activity while improving the off-target effect, thereby improving the safety of siRNA.

[0204] Table 7

[0205]

[0206]

[0207] Example 7 In vivo activity of siRNAs containing different chemical modifications in HDI mice

[0208] In this example, based on the in vitro on-target and off-target evaluation results, siRNA was selected for conjugation synthesis, and the in vivo activity was evaluated in the HDI mouse model. The siRNA conjugate was synthesized as in Example 2 by solid phase synthesis.

[0209] At least 14 days before the administration of the conjugate, six to eight-week-old female Balb / C mice (Zhejiang Weitong Lihua) were injected with high-pressure tail vein injection to construct humanized mice expressing PD-L1, and 2 μg of plasmids containing PD-L1 mRNA sequences were injected into mice through the tail vein within 5-7 seconds to produce PD-L1-SEAP model mice (Zhang G et al., "High levels of offoreign gene expression in hepatocytes after tail vein injection of nakedplasmid DNA." Human Gene Therapy 1999 Vol. 10, p1735-1737.). The inhibition of PD-L1 expression by PD-L1 siRNA conjugates leads to the inhibition of secretory alkaline phosphatase (SEAP) expression. One day before administration, blood was collected by orbital bleeding, and the SEAP expression level in serum was measured using the Phospha-Light SEAP reporter gene analysis system (Invitrogen) according to the product manual, and mice were grouped according to the average SEAP level. The experimental group mice were given the conjugate, and the vehicle group mice were given phosphate buffered saline (PBS), and the conjugate was administered subcutaneously at a dose of 3 mg / kg per mouse. Blood was collected again 7 days and 28 days after administration, and serum was collected. According to the product instructions, the Phospha-Light SEAP reporter gene analysis system (Invitrogen) was used to measure the SEAP expression level in the serum. The SEAP level of each animal after administration was divided by the SEAP level of the animal before administration to determine the expression ratio "normalized to before treatment".

[0210] The results were expressed as the residual expression level of serum SEAP before and after administration in each group (the vehicle group was 100%). The relative residual expression level results are shown in Table 8 and Figure 2 As shown, 7 days after administration, the conjugates SD004177, SD004178, SD004179, SD004240, SD004180, SD004241, SD004242, SD004181, and SD004182 had good activity, with inhibition rates greater than 80%. 28 days after administration, the SD004178 and SD004180 compounds still maintained greater than 80% activity, reflecting long-term effectiveness.

[0211] Table 8

[0212]

[0213] This embodiment uses the HDI model to detect human PD-L1 gene levels in vivo, thereby better predicting the in vivo activity of human PD-L1 mRNA and providing more and more reliable experimental data for clinical trials and drug marketing.

[0214] Example 8 In vivo efficacy of siRNA in the hPD-1 / PD-L1 humanized mouse AAV-HBV (hepatitis B virus) model

[0215] In this example, the in vivo efficacy of siRNA in the hPD-1 / PD-L1 humanized mouse AAV-HBV model was evaluated to test the anti-HBV activity. The siRNA conjugate was synthesized as in Example 2 by solid phase synthesis.

[0216] Six weeks before the administration of the conjugate, an hPD-1 / PD-L1 humanized mouse AAV-HBV model was constructed. A mouse animal model of persistent HBV infection was prepared by intravenous injection of rAAV8-1.3HBV into the tail vein of 6-8 week-old B6-hPD-1 / PD-L1 female mice. The AAV virus injection dose was 1E+11vg / mouse. Six weeks after the virus injection, the animals were submandibularly blooded and centrifuged after blood collection. The centrifugation conditions were 5000rpm, 4°C, and centrifuged for 10 minutes. The serum was diluted with PBS, and the dilution multiple should be determined according to the actual situation. The diluted samples were then sent to Beijing Dian Medical Testing Laboratory Co., Ltd. for HBsAg (hepatitis B surface antigen) testing, and the measurement results were back-calculated according to the dilution multiple. The HBsAg quantification method is direct electrochemiluminescence. The animals were grouped according to HBsAg levels. On day 0, they were injected subcutaneously with a dose of 7.5 mg / kg body weight once a week. Blood was collected on day 49 to detect HBsAg levels and evaluate the anti-HBV activity of siRNA.

[0217] The reduction of HBsAg 49 days after administration is shown in Table 9. The results show that both SD004178 and SD004180 can significantly reduce HBsAg levels.

[0218] Table 9

[0219]

[0220]

[0221] The above detailed description of the present invention is intended to enable persons familiar with the art to understand the contents of the present invention and implement them. It does not limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A siRNA comprising a sense strand and an antisense strand, Features: Each nucleotide in the siRNA is independently a modified or unmodified nucleotide; the sense strand is AGAUGAGGAUAUUUGCUGU (SEQ ID NO.3), and the antisense strand is ACAGCAAAUAUCCUCAUCUUU (SEQ ID NO.15); or, the sense strand is AGAUGAGGAUAUUUGCUGA (SEQ ID NO.11), and the antisense strand is UCAGCAAAUAUCCUCAUCUUU (SEQ ID NO.23).

2. The siRNA according to claim 1, Features: The modified nucleotides are 2'-methoxy modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-CH 2 -CH 2 -O-CH 3 Modified nucleotides, 2'-O-CH 2 -CH=CH 2 Modified nucleotides, 2'-CH 2 -CH 2 -CH=CH 2 Modified nucleotides, 2'-deoxy nucleotides, 2'-methoxyethyl modified nucleotides, phosphorothioate modified nucleotides, VP modified nucleotides, LNA, ENA, cET BNA, UNA, GNA and One or more combinations of, wherein R1 is H, OH or CH 3 , Base is a natural nucleobase.

3. The siRNA according to claim 1 or 2, Features: One or more nucleotides in the sense strand or the antisense strand are modified nucleotides.

4. The siRNA according to claim 1 or 2, Features: From 5' to 3', the nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; from 5' to 3', the nucleotides at positions 2, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at positions other than positions 2, 6, 7, 14 and 16 of the antisense strand are 2'-methoxy-modified nucleotides; at least one of the following connections between nucleotides in the siRNA is a phosphorothioate connection: The connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand; The 3' end of the sense strand is a phosphorothioate group, and the 5' end of the antisense strand is a VP-modified nucleotide.

5. The siRNA according to claim 1 or 2, Features: From the 5' to 3' direction, the 6th position of the antisense strand is a 2'-fluoro-modified nucleotide or , the 7th position of the antisense strand is a 2'-methoxy modified nucleotide or , wherein R1 is H, OH or CH 3 , Base is a natural nucleobase.

6. The siRNA according to claim 5, Features: The nucleotide at position 6 or 7 of the antisense strand is .

7. The siRNA according to claim 1, Features: The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmUm, and the antisense strand is AmsCfsAmGmCmAfAmAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm.

8. The siRNA according to claim 1, Features: The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmUm, and the antisense strand is AmsCfsAmGmCmAgoAmAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm; or, The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmUm, and the antisense strand is AmsCfsAmGmCmAfAgoAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm; or, The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmAm, and the antisense strand is VPUmsCfsAmGmCmAfAmAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm; or, The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmAm, and the antisense strand is VPUmsCfsAmGmCmAgoAmAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm; or, The sense strand of the siRNA is AmsGmsAmUmGmAmGfGfAfUmAmUmUmUmGmCmUmGmAm, and the antisense strand is VPUmsCfsAmGmCmAfAgoAmUmAmUmCmCmUfCmAfUmCmUmsUmsUm.

9. An siRNA conjugate, Features: It comprises the siRNA according to any one of claims 1 to 8, and a conjugation group conjugated to the siRNA.

10. The siRNA conjugate according to claim 9, Features: The conjugated group is derived from compound SA51. The number of compound SA51 in the conjugated group is 2 to 4, and the 2 to 4 compounds SA51 are sequentially connected by chemical bonds. The structural formula of the compound SA51 is: 。 11. The siRNA conjugate according to claim 9 or 10, Features: The conjugated group is linked to the 3' end and / or the 5' end of the sense strand.

12. The siRNA conjugate according to claim 9, Features: The structural formula of the siRNA conjugate ; in, represents the duplex formed by the siRNA of the present disclosure, and X is O or S.

13. A pharmaceutical composition, Features: It comprises the siRNA according to any one of claims 1 to 8 or the siRNA conjugate according to any one of claims 9 to 12, and a pharmaceutically acceptable carrier or excipient.

14. The pharmaceutical composition according to claim 13, Features: The pharmaceutical composition is used for inhibiting the expression of programmed cell death-ligand 1 gene.

15. Use of the siRNA according to any one of claims 1 to 8, or the siRNA conjugate according to any one of claims 9 to 12, or the pharmaceutical composition according to claim 13 or 14 for preparing a medicament for treating and / or preventing a disease associated with PD-L1 gene expression; the disease is viral hepatitis or cancer.

16. The use according to claim 15, Features: The viral hepatitis is caused by infection with hepatitis B virus, hepatitis C virus, or hepatitis D virus.